Canada: Proposed Canadian Amendments Will Affect Innovative Drug Companies

Last Updated: October 21 2005

By Conor McCourt

This article first appeared in the May/June 2005 issue of Update. Reprinted with the permission of the Food and Drug Law Institute (FDLI) © 2005.

The government of Canada recently published proposed amendments1 to the Patented Medicines (Notice of Compliance) Regulations2 and to the Food and Drug Regulations3 that will affect innovative drug companies. These regulations create the regulatory framework that, together with patent enforcement proceedings under Canada’s Patent Act,4 governs the protection of pharmaceutical patents. The proposed amendments seek to alter this regulatory framework as follows:

  • restricting the application of the Patented Medicine (Notice of Compliance) Regulations, most notably by limiting an innovator’s ability to list and enforce patents on the patent register maintained by the Minister of Health; and
  • enhancing protection for the data that an innovator is required to submit to the Minister of Health as part of its new drug submission, and extending the period of data protection from five to eight years (eight and a half years for pediatric studies).

Changes to the Patented Medicines (Notice of Compliance) Regulations

The Patented Medicines (Notice of Compliance) Regulations permit an innovator that files a new drug submission or supplementary new drug submission to submit certain patents for inclusion on the patent register. The patent register lists patents for medicinal products that have been approved by the Minister of Health for sale in Canada.

Listed patents are afforded certain protections. When a generic pharmaceutical company seeks marketing approval for its product by comparing it to an innovator’s reference product for which there is a listed patent, the generic manufacturer must either accept the fact that marketing approval of its product cannot be issued until the listed patent expires or serve the innovator with a notice of allegation. That notice must specify why the listed patent should not prevent the generic competitor from marketing its product before the expiry of the listed patent. The Patented Medicines (Notice of Compliance) Regulations permit the innovator to commence legal proceedings in response to the notice of allegation. The proceedings trigger an automatic stay of marketing approval for the generic product for up to 24 months.

The proposed amendments to the Patented Medicines (Notice of Compliance) Regulations will change the regime in three important ways.

First, the proposed amendments would restrict the type of patents that may be listed on the patent register. Currently, patents are eligible for inclusion on the patent register if they contain claims for the medicine contained in the product for which approval is sought; claims to formulations containing that medicine; and claims for indications involving the medicine. Moreover, under the current regime, a patent that relates to a formulation that is different from the approved product is still eligible for listing, as is a patent that claims an off-label indication.

Furthermore, the proposed amendments would restrict the type of patents listed on the patent register to those that include claims to the compound, formulation, or indication for which approval is sought—in other words, to patents that cover the approved product. For practical purposes, this amendment would have the most serious impact on patents that until now have been eligible for inclusion on the patent register in connection with supplementary new drug submissions. In addition, certain types of supplementary new drug submissions in respect of which patents can be listed have been excluded from the operation of the Patented Medicines (Notice of Compliance) Regulations. These excluded supplementary new drug submissions are those seeking approval for 1) brand name changes; 2) manufacturing site changes; 3) process changes; 4) quality control (specification) changes; 5) label changes; 6) dosage form changes; 7) safety profile changes; and 8) withdrawal period amendments. Basically, this leaves only supplementary new drug submissions that relate to new formulations or indications as being included.

Second, the proposed amendments would alter the existing requirement that a generic competitor must address all patents listed on the patent register, including newly added patents. Under the proposed amendments, a generic competitor would have to address a newly added patent only if it were added in relation to an innovator’s supplementary new drug submission, and then only if that submission were filed prior to the filing of a generic competitor’s request for marketing approval of its product.

Third, the proposed amendments would expand the type of allegation that a generic competitor may make in a notice of allegation. At present, a generic competitor typically will allege that its proposed product will not infringe the listed patent and/or that the listed patent is invalid. The proposed amendments would permit a generic competitor to make two additional allegations: 1) that the innovator has falsely certified a patent’s eligibility for inclusion on the patent register; and 2) that in the case of a patent listed against a supplementary new drug submission for a new use, the generic competitor is not seeking approval for the claimed use.

The proposed amendments contain both an anti-avoidance provision and a grandfathering provision. Under the anti-avoidance provision, an innovator that withdraws its original approved product to prevent generic competitors from using it as comparison will lose the protection of the Patented Medicines (Notice of Compliance) Regulations for all patents listed on the patent register for that approved medicine.

The grandfathering provision stipulates that patents on the patent register as of the date the amendments come into force will remain on the register and will be subject to the listing requirements as they existed prior to that date.

Enhanced Data Protection

The proposed amendments will render meaningful the protection for innovators under the data protection provisions of the Food and Drug Regulations and extend the period of data protection from five to eight years.

In Canada, generic competitors generally must demonstrate the bioequivalence of their product to an approved medicine before their product will be approved for sale by Health Canada. Generic competitors demonstrate this bioequivalence by comparing their product with the product of the innovator. Existing data protection provisions in the Food and Drug Regulations are intended to guarantee the confidentiality and non-use of an innovator’s data—and hence prevent a generic competitor from making the comparison—for a period of five years. The courts have interpreted the provisions so narrowly, however, as to be ineffective.

The proposed amendments would prohibit the granting of a notice of compliance to a party that directly or indirectly compares its drug to an innovator’s drug, if the comparison forms the basis on which the party seeks approval and if the medicinal ingredient in the party’s drug is identical to the medicinal ingredient in the innovator’s drug. This prohibition would last for a period of eight years from the first notice of compliance granted to the innovator for the drug in question. If the first notice of compliance to the innovator is based on studies that include pediatric studies, the period of prohibition is eight and a half years.

The deadline for filing submissions with the government of Canada on these proposed amendments was February 24, 2005. The government is assessing these submissions to determine whether to modify the proposed amendments and then promulgate them or whether to republish the proposed amendments if the changes that the government makes to them warrant republication.


2. S.O.R./1993-133. Available at (last visited May 4, 2005).

3. C.R.C., c. 870. Available at (last visited May 2, 2005).

4. R.S.C. 1985, c. P-4. Available at (last visited May 4, 2005).

Mr. McCourt is a partner in the Intellectual Property Department in the Toronto office of Torys LLP.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.